Review Article

Potential Inhibitors for Isocitrate Lyase of *Mycobacterium tuberculosis* and Non-*M. tuberculosis*: A Summary

Yie-Vern Lee,¹ Habibah A. Wahab,^{2,3} and Yee Siew Choong^{1,4}

¹Institute For Research in Molecular Medicine, Universiti Sains Malaysia, 11800 Minden, Penang, Malaysia

²Pharmaceutical Design and Simulation Laboratory, School of Pharmaceutical Sciences, Universiti Sains Malaysia, 11800 Minden, Penang, Malaysia

³Natural Product and Drug Discovery Centre, Malaysian Institutes of Pharmaceuticals and Nutraceuticals, National Institutes of Biotechnology Malaysia, Ministry of Science, Technology and Innovation, Block 5-A, Halaman Bukit Gambir, 11700 Penang, Malaysia

⁴ADAPT Research Cluster, Centre for Research Initiatives, Clinical & Health Sciences, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia

Correspondence should be addressed to Yee Siew Choong; yeesiew@usm.my

Received 3 July 2014; Revised 1 December 2014; Accepted 1 December 2014

Academic Editor: Yudong Cai

Copyright © 2015 Yie-Vern Lee et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Isocitrate lyase (ICL) is the first enzyme involved in glyoxylate cycle. Many plants and microorganisms are relying on glyoxylate cycle enzymes to survive upon downregulation of tricarboxylic acid cycle (TCA cycle), especially *Mycobacterium tuberculosis* (MTB). In fact, ICL is a potential drug target for MTB in dormancy. With the urge for new antitubercular drug to overcome tuberculosis treat such as multidrug resistant strain and HIV-coinfection, the pace of drug discovery has to be increased. There are many approaches to discovering potential inhibitor for MTB ICL and we hereby review the updated list of them. The potential inhibitors can be either a natural compound or synthetic compound. Moreover, these compounds are not necessary to be discovered only from MTB ICL, as it can also be discovered by a non-MTB ICL. Our review is categorized into four sections, namely, (a) MTB ICL with natural compounds; (b) MTB ICL with synthetic compounds; (c) non-MTB ICL with natural compounds; and (d) non-MTB ICL with synthetic compounds. Each of the approaches is capable of overcoming different challenges of inhibitor discovery. We hope that this paper will benefit the discovery of better inhibitor for ICL.

1. Introduction

1.1. Isocitrate Lyase. According to the ENZYME nomenclature database, isocitrate lyase (ICL; E.C. number 4.1.3.1) is also known as isocitrane, isocitritase, isocitratase, and isocitrate glyoxylate-lyase [1]. ICL can be found in Archaea, bacteria, fungi, nematodes, plants, and protists. In general, ICL plays an important role in seed germination in higher plants, microbial pathogenicity, and survival.

Glyoxylate cycle is an alternative pathway to generate energy when tricarboxylic acid cycle (TCA cycle or Krebs cycle) is downregulated upon oxygen and nutrient depletion [2]. When most of the TCA enzymes are suppressed, glyoxylate enzymes will be upregulated. By utilizing glyoxylate cycle, some beta oxidation steps in TCA cycle are bypassed. The early phase of glyoxylate cycle resembles the TCA cycle (Figure 1), and the acetyl-CoA is the only substrate for both

TCA and glyoxylate cycle. However, the source of precursor, acetyl-CoA, is different for respective cycle. Carbohydrate undergoes glycolysis to generate the acetyl-CoA while lipid undergoes beta-oxidation to generate acetyl-CoA. The point of differentiation for these two cycles begins when acetyl-CoA is converted to isocitrate. In glyoxylate cycle, two important enzymes are required: ICL and malate synthase (MS). ICL carries the function to reversibly cleave the isocitrate to glyoxylate and succinate while MS will convert glyoxylate into malate by adding an acetyl group. Earlier study showed that during downregulation of TCA cycle, the inhibition of ICL is fatal for MTB [3].

To date, a total of seven ICL crystal structures were solved for five different microorganisms: *Aspergillus nidulans* [PDB id: 1DQU [4]], *Mycobacterium tuberculosis* [PDB id: 1F6I [5]; 1F8I [5]; 1F8M [5]], *Escherichia coli* [PDB id: 1IGW [6]], *Burkholderia pseudomallei* [PDB id: 3I4E (paper

FIGURE 1: The general scheme for tricarboxylic acid (TCA) cycle (blue bold arrows) and glyoxylate cycle (green arrows). Isocitrate lyase (ICL, circled in red) is the first enzyme involved in the glyoxylate cycle. Oxaloacetate might leave the cycle as the substrate of gluconeogenesis (red dash arrow).

unpublished)), *Brucella melitensis* [PDB id: 3EOL, 3P0X, 3OQ8, and 3E5B (paper unpublished)], and *Yersinia pestis* [PDB id: 3LG3 (paper unpublished)]. However, no plant ICL structure has been solved. Only a handful of crystal structures were obtained for ICL as it is likely due to the difficulty in controlling the evaporation rate of crystallizing solution [7].

1.2. MTB ICL Related Studies. The structure of MTB ICL (Figure 2) was solved by Sharma et al. [5] (PDB id: 1F61, 1F81, 1F8M). Current available data showed that ICL is stable as a dimer but it will only be functional in a tetrameric form [5, 8]. Each subunit has an unusual α/β barrel as its largest core domain which consists of eight α -helices and β -strands, respectively. An extra α -helix was projected out from the barrel of each subunit with another two ensuing α -helices which are involved in the interaction with neighboring subunit. On top of the barrel, there is an important small β -domain with several active side residues. 1F61 is a ligand-free ICL which has “open conformation” active site. 1F81 and 1F8M are ICL that bind succinate/glyoxylate and pyruvate, respectively. Ligand binding leads to conformational change triggering the ICL active site to shift into a “close conformation.” The catalytic mechanism of forming isocitrate from glyoxylate, succinate, and vice versa was mentioned. Glyoxylate was

proposed to bind with ICL first before succinate as the former buried deeper than the latter. As per the cleavage mechanism of isocitrate to glyoxylate and succinate, the authors proposed that isocitrate C–C bond cleaved via Claisen condensation. However, the cleavage information from isocitrate-ICL complex structure is needed, which is unavailable at the moment to further confirm the abovementioned hypothesis.

The potential of ICL as a drug target has been proven by several studies. According to Dunn et al., [9] ICL gene is not found in mammals; therefore theoretically it is safe if a drug targeting at ICL is administrated to human. Muñoz-Elías and McKinney [3] showed that two types of MTB ICLs (ICL1: prokaryotic-like isoform and ICL2: eukaryotic-like isoform) are jointly required for MTB survival. They showed that absence of either one ICL isoform will not harm the survival of MTB but absence of both isoforms will cause MTB to be eliminated from the host lungs. These two ICL isoforms are coded by *icl* gene (ICL1) and *ace A* gene (ICL2), respectively [10]. Current research involving ICL is mainly focused on ICL1 (including the solved structure of ICL). Another isoforms, the *ace A* gene, is however less active compared to *icl* gene and is not expressed in all mycobacterium strain [11]. Furthermore, Gould et al. [12] reported that MTB ICL1 has dual roles, in both glyoxylate cycle and

FIGURE 2: The structure of *Mycobacterium tuberculosis* isocitrate lyase in ribbon representation. (a) ICL tetramer with each subunit is represented by different colors [5]. (b) ICL monomer with active site (in cyan color) in “open conformation” and (c) ICL monomer with active site (in cyan color) in “close conformation” substrates (succinate and glyoxylate) are bound in the active site with red CPK representation.

methylcitrate cycle. Methylcitrate cycle is a mechanism that removes propionyl-CoA, a toxic by-product of lipid beta-oxidation. Three enzymes involved in methylcitrate cycle are methylcitrate synthase, methylcitrate dehydrogenase, and 2-methylisocitrate lyase (MCL). It was found that MTB only produce methylcitrate synthase and methylcitrate dehydrogenase but not MCL. The function of MCL was carried out by ICL1, making it more important than expected [12].

Singh and Ghosh highlighted that both ICL and isocitrate dehydrogenase (IDH) compete for the same substrate, which is the isocitrate [13]. A new approach to inhibit ICL by increasing the IDH's concentration was demonstrated. This is also indicative that IDH has higher affinity towards isocitrate compared to ICL. However, IDH-kinase counter inhibits IDH action, thus allowing ICL to bind isocitrate and proceed through the glyoxylate pathway. IDH-kinase was also proposed as a potential drug target for IDH-kinase inhibition which could lead to ICL inhibition [13].

Till date, several ICL inhibitors like itaconate [14], 3-nitropropionate [15], and 3-bromopyruvate [16] have been identified. However, these inhibitors are not suitable as drug due to their toxicity and their ability to inhibit key metabolism enzymes *in vivo*. For example, itaconate was suspected to cause hypertonicity of blood pressure in cats [17] and affects the growth of rats [18]; 3-nitropropionate was found to cause neurotoxicity [19] whereas 3-bromopyruvate seems to be an energy blocker [20, 21]. To date, various research groups are seeking new potential inhibitor for ICL.

The inhibitors screening approaches are similar but targeted the ICL from different species and are summarized in next sections.

2. Discovery of Isocitrate Lyase Potential Inhibitors from Different Approaches

Among all species, ICL of *Mycobacterium tuberculosis* (MTB) gains the most attention as it is related to tuberculosis, which had infected one-third of the world population [22]. As MTB survives in both active and inactive (dormant) phase with different metabolic pathway, identification of common drug target for these two phases that utilize different metabolic pathways is rather difficult. Therefore, MTB drug target study for each respective phase is important [23]. Active MTB operates TCA cycle, using sugar as main carbon source to generate energy. However, phagocytosis of MTB by macrophage causes oxygen and nutrient depletion, causing MTB to enter its dormant phase. This causes a massive metabolic shunt and downregulates TCA enzymes [24]. In order to maintain MTB viability, glyoxylate enzymes will be upregulated in order to continue generating energy from an alternative carbon source, namely, lipids. Other than MTB, similar enzyme regulation in TCA and glyoxylate cycle has been observed in other opportunistic pathogens such as bacterium (*Pseudomonas aeruginosa* [25]), fungus (*Candida albicans* [26], *Magnaporthe grisea* [27], and *Leptosphaeria maculans* [28]), and nematode (*Caenorhabditis elegans* and

Ascaris suum [29]). Due to the importance of ICL during glyoxylate cycle towards various microorganisms, ICL has been studied intensively.

MTB ICL is one of the most difficult organism/enzyme to study as it grows slow and has a higher risk of infection. Biosafety level three training and facility are necessary to study live MTB. Therefore, several strategies to screen ICL inhibitor were derived. The source of ICL used for ICL inhibitor studies is categorized into MTB and non-MTB ICL, respectively. The source of inhibitor however could either be natural or synthetic compounds (Table 1).

2.1. MTB ICL with Natural Compound. First high-throughput screening (HTS) report on natural compound using MTB ICL was released on 2006 by Bai and coworkers [30]. A total of 465 traditional Chinese medicines were screened against MTB ICL. Two extracts, *Zingiber officinale* (IC₅₀ of 47.7 µg/mL) and *Illicium verum* (IC₅₀ of 18.2 µg/mL), were reported to have inhibitory effect. In 2010, a subsequent article was released, reporting a novel lead compound I2906 (1-ethyl-4-hydroxy-2-oxo-N'-tridecanoyl-1,2-dihydroquinoline-3-carbohydrazide) with an IC₅₀ of 134.4 µg/mL [31]. Chelerythrine extract from the plant *Chelidonium majus* was also reported as a potential drug which causes fivefold decrease in ICL gene expression [32].

2.2. MTB ICL with Synthetic Compound. The common strategy to obtain synthetic compounds is to obtain analog or derivatives of existing potential inhibitor, regardless of MTB or non-MTB ICL. The ultimate goal of this strategy is not only to look for new inhibitors, but also to improve the inhibitory potential of existing ones. A thorough review for synthetic compounds targeting MTB ICL is available [33, 34]. The review articles have reviewed the synthetic compounds such as phthalazinyl derivatives [35], phthalazin-4-ylacetamides [36], 5-nitro-2-furoic acid hydrazones with furan-2-carbaldehyde [37], 5-Nitro-2,6-dioxohexahydro-4-pyrimidinecarboxamides [38], isatinyl thiosemicarbazones derivatives [39], and 3-nitropropionamide derivatives [40] with 45–61%, 40.62–66%, 86.8%, 45.7%, and 63.44% inhibition at 10 µM and IC₅₀ of 0.1 µM, respectively.

Other than derivative synthesis, other categories of synthetic compound such as DNazymes [41], Mannich bases [42], peptide inhibitors [43, 44], and pyruvate-isoniazid analog with their copper complex [45] also gained some attention in the crowd. In 2005, the concept of silencing the *icl* gene by DNazymes was introduced. The study showed that several designed DNazymes (DZ1, DZ3, DZ4, and DZ5) were capable of specifically cleave ICL mRNA, which leads to interruption of ICL expression in macrophage. However, DNzyme did not show any effect toward *in vitro* MTB growth when combined with another inhibitory drug such as isoniazid [41]. Later Mannich base, Ydcm67, was reported as one of the best inhibitors (57.4% inhibition at 0.05 mg/mL) out of 124 Mannich bases screened, but no *in vivo* data is shown [42]. For peptide inhibitors, 38.82–47.92% inhibition rate was obtained but the authors concluded that these peptide inhibitors might be too small in size and might face some drug delivery issue [43]. However, in 2013, the subsequent

article has made some optimization for the peptide inhibitors. Liu et al. first screen a phage peptide library against MTB ICL to obtain 29 potential inhibitors and perform molecular docking simulation to confirm the hit. Liu and coworker managed to synthesize the 12 peptides out of 29 that were shown to have successfully docked into ICL crystal structure using Ligand Fit module of Discovery Studio 2.1 software (PDB id 1F8M) and one of the peptides has obtained as high as IC₅₀ of 126 µM in bioassay [44]. Regarding pyruvate-isoniazid analog with its copper complex, preliminary result of 6–92% ICL inhibition still requires further investigation to its inhibitory mechanism [45].

2.3. Non-MTB ICL with Natural Compound. Natural compounds are well known in certain parts of the world with remedial potential. The search for ICL inhibitors has also expanded to screen natural products and to date, marine sponges and algae are the most common species explored. Several ICL inhibitors from these sources were discovered using ICL of *Magnaporthe grisea* and *Candida albicans*. Compounds discovered through *M. grisea* are halisulfate 1 (*Hippospongia* spp.) [46, 47] and bromophenol (*Odonthalia corymbifera*) [27] with IC₅₀ of 12.6 µM and 2.0–2.8 µM, respectively, whereas, compounds discovered through *C. albicans* ICL are meroditerpenoids [48] (*Sargassum siliquastrum*), dihydroxystyrene metabolites [49] (association of *Poecillastra wondoensis* and *Jaspis* sp.), sesterterpenoids [50] (*Sarcotragus* sp.), sesterterpene sulfates [51] (*Dysidea* sp.), hyrtiosin B [52] (*Hyrtios* sp.), sargachromanols [53] (*Sargassum siliquastrum*), scalarane sesterterpenes [54] (*Hyatella* sp.), suvanine salt [55] (*Coscinoderma* sp.), bahamaolides A [56] (*Streptomyces* sp.), beta-carboline alkaloid [57] (*Synoicum* sp.), sphingolipid [58] (*Spirastrella abata*), and tris-aromatic furanones [59] (*Synoicum* sp.). Their IC₅₀ are 50–95 µg/mL, 28.7 to >200 µg/mL, 12.5–19.9 µg/mL, 31.3–33.8 µM, 89 µM, 118.4–172.9 µM, 40.8–55.3 µM, 5–17 µM, 10.8 µM, 48.2–68.9 µM, 2–87 µM, and 7.62–10.36 µM, respectively. Other compounds which are also included in this category are Mycenon [60] (*Mycena* sp.) that is discovered through *Neurospora crassa* and *Ricinus communis* ICL with IC₅₀ of 5.2–7.4 µM and also polyoxygenated diterpenes [61] (*Phorbas* sp.) that is discovered through (unspecified) ICL with weak inhibition LC₅₀ of 55–140 µg/mL.

2.4. Non-MTB ICL with Synthetic Compounds. Three most established inhibitors for ICL were synthetic compounds discovered through non-MTB ICL: itaconate [14], 3-nitropropionate [15], and 3-bromopyruvate [16] with inhibition constant *K_i* of 120, 120 and 3 µM, respectively [11]. These inhibitors are analog of succinate (itaconate, 3-nitropropionate) and glyoxylate (3-nitropropionate). However, these inhibitors are not being developed into drug as they are toxic and inhibit some key metabolism enzymes at *in vivo* level. Itaconate was suspected to cause hypertonicity towards cat blood pressure [17] affecting the growth of rats [18]; 3-nitropropionate was found to cause neurotoxicity [19] whereas 3-bromopyruvate seems to be an energy blocker [20, 21]. Therefore, these inhibitors were often used as control experiments in ICL inhibitors studies only.

TABLE 1: Summary of potential inhibitors for MTB and non-MTB isocitrate lyase (ICL).

Number	Published year	Inhibitor	Source	Description	Target ICL	Inhibition * (IC ₅₀)	Remarks
1	1977	<div>Itaconate [11, 14] </div>	Synthetic	Succinate analog	<i>Pseudomonas indigofera</i>	$K_i = 120$	Established inhibitor
2	1982	<div>3-Nitropropionate [11, 15] </div>	Synthetic	Succinate analog	<i>Pseudomonas indigofera</i>	$K_i = 120$	Established inhibitor
3	1990	<div>Mycenon [60] </div>	<i>Mycena</i> sp.	Fungi	<i>Acinetobacter calcoaceticus</i> <i>Neurospora crassa</i> <i>Ricinus communis</i>	5.2 μ M 7.4 μ M	No information on positive control
4	1990	<div>3-Bromopyruvate [11, 16] </div>	Synthetic	Glyoxylate analog	<i>Escherichia coli</i>	3 μ M	Established inhibitor

TABLE 1: Continued.

Number	Published year	Inhibitor	Source	Description	Target ICL	Inhibition * (IC ₅₀)	Remarks
5	2005	DNAzyme [41]	Synthetic	—	<i>Mycobacterium tuberculosis</i>	—	Positive control IC ₅₀ of itaconate = 90 µg/mL (good inhibitory)
6	2006	Extract of traditional Chinese medicine [30]	<i>Zingiber officinale</i> , <i>Illicium verum</i>	Plant	<i>Mycobacterium tuberculosis</i>	47.7 µg/mL 18.2 µg/mL	
Hydroquinone derivatives [62]							
7	2007		Synthetic	—	<i>Candida albicans</i>	0.28–1.02 mM	Positive control IC ₅₀ of itaconate = 0.06 mM (weak inhibitory)
Halisulfate 1 [46, 47]							
8	2007		<i>Hippospongia</i> sp.	Marine sponge	<i>Magnaporthe grisea</i>	12.6 µM	No information on positive control (high inhibitory)
Bromophenols [27]							
9	2007		<i>Odonthalia corymbifera</i>	Red algae	<i>Magnaporthe grisea</i>	2.0–2.8 µM	Positive control IC ₅₀ of 3-nitropropionate = 94.2 µM (high inhibitory)

TABLE I: Continued.

Number	Published year	Inhibitor	Source	Description	Target ICL	Inhibition * (IC ₅₀)	Remarks
Polyoxygenated diterpenes [61]

10	2008		<i>Phorbas</i> sp.	Marine sponge	—	LC ₅₀ of 55–140 µg/mL	No information on positive control (weak inhibitory)

Meroditerpenoids [48]							
11	2008		<i>Sargassum siliquastrum</i>	Brown algae	<i>Candida albicans</i>	50–95 µg/mL	No information on positive control (weak inhibitory)

TABLE 1: Continued.

Number	Published year	Inhibitor	Source	Description	Target ICL	Inhibition * (IC ₅₀)	Remarks
Dihydroxystyrene metabolites [49]							
12	2008		Association of <i>Poecillastra wondensis</i> and <i>Jaspis</i> sp.	Marine sponge	<i>Candida albicans</i>	28.7 to >200 µg/mL	Positive control IC ₅₀ of itaconate = 5.8 µg/mL (weak to moderate inhibitory)
Sesterterpenoids [50]							
13	2008		<i>Sarcotragus</i> sp.	Marine sponge	<i>Candida albicans</i>	12.5–19.9 µg/mL	Positive control IC ₅₀ of Itaconate = 4.9 µg/mL (moderate to high inhibitory)
Sesterterpene sulfates [51]							
14	2008		<i>Dysidea</i> sp.	Marine sponge	<i>Candida albicans</i>	31.3–33.8 µM	Positive control IC ₅₀ of 3-nitropropionate = 50.7 µM (high inhibitory)

TABLE 1: Continued.

Number	Published year	Inhibitor	Source	Description	Target ICL	Inhibition* (IC ₅₀)	Remarks
Phthalazinyl derivatives [35]							
15	2009		Synthetic	—	<i>Mycobacterium tuberculosis</i>	45–61% inhibition at 10 μ M	Positive control 3-nitropropionate has 63.2% inhibition at 100 μ M
Hyrtiosin B [52]							
16	2009		<i>Hyrtios</i> sp.	Marine sponge	<i>Candida albicans</i>	89 μ M	Positive control IC ₅₀ of 3-nitropropionate = 50.7 μ M (high inhibitory)
Phthalazin-4-ylacetamides [36]							
17	2010		Synthetic	—	<i>Mycobacterium tuberculosis</i>	40.62–66% inhibition at 10 μ M	Positive control 3-nitropropionate has 68.2% inhibition at 100 μ M

TABLE 1: Continued.

Number	Published year	Inhibitor	Source	Description	Target ICL	Inhibition* (IC ₅₀)	Remarks
Extract of traditional Chinese medicine (I2906) [31]							
18	2010		—	Plant	<i>Mycobacterium tuberculosis</i>	134 µg/mL	Control samples were untreated samples
5-Nitro-2-furoic acid hydrazones with furan-2-carbaldehyde [37]							
19	2010		Synthetic	—	<i>Mycobacterium tuberculosis</i>	86.8% inhibition at 10 mM	Positive control 3-nitropropionate has 63.2% inhibition at 100 µM (good inhibitory)
Bromophenols [63]							
20	2010		Synthetic	—	<i>Candida albicans</i>	2.65 µM	Positive control IC ₅₀ of 3-nitropropionate = 50.7 µM (high inhibitory)
5-Nitro-2,6-dioxohexahydro-4-pyrimidinecarboxamides [38]							
21	2010		Synthetic	—	<i>Mycobacterium tuberculosis</i>	45.7% inhibition at 10 mM	Positive control 3-nitropropionate has 68.2% inhibition at 100 µM (good inhibitory)
Indole-containing natural compound (analog) [64]							
22	2010		Synthetic	—	<i>Candida albicans</i>	75 µM	Positive control IC ₅₀ of 3-nitropropionate = 50 µM (high inhibitory)

TABLE I: Continued.

Number	Published year	Inhibitor	Source	Description	Target ICL	Inhibition * (IC ₅₀)	Remarks
Isatinyl thiosemicarbazones derivatives [39]							
23	2010		Synthetic	—	<i>Mycobacterium tuberculosis</i>	63.44% inhibition at 10 mM	Positive control 3-nitropropionate has 65.9% inhibition at 100 mM (good inhibitory)
Brominated resorcinol dimer [65]							
24	2011		Synthetic	—	<i>Candida albicans</i>	28 μM	Positive control IC ₅₀ of 3-nitropropionate = 6.0 μM (good inhibitory)
Sargachromanols [53]							
25	2011		<i>Sargassum siliquastrum</i>	Brown algae	<i>Candida albicans</i>	118.4–172.9 μM	Positive control IC ₅₀ of 3-nitropropionate = 34.8 μM (moderate inhibitory)

TABLE I: Continued.

Number	Published year	Inhibitor	Source	Description	Target ICL	Inhibition* (IC ₅₀)	Remarks
26	2011	Scalarane sesterterpenes [54]	<i>Hyatella</i> sp.	Marine sponge	<i>Candida albicans</i>	40.8–55.3 μ M	Positive control IC ₅₀ of 3-nitropropionate = 279 μ M (weak inhibitory)
27	2011	Suvaranine salt [55]	<i>Coccinoderma</i> sp.	Marine sponge	<i>Candida albicans</i>	5–17 μ M	Positive control IC ₅₀ of 3-nitropropionate = 279 μ M (moderate inhibitory)
28	2011	Chelerythrine extract [32] Mannich base, Ydcm67 [42]	<i>Chelidonium majus</i>	Plant	<i>Mycobacterium tuberculosis</i>	Expression level decreased 5 fold	—
29	2011		Synthetic	—	<i>Mycobacterium tuberculosis</i>	57.4% inhibition at 0.05 mg/mL	Positive control oxalic acid has 95.55% inhibition at 0.05 M

TABLE 1: Continued.

Number	Published year	Inhibitor	Source	Description	Target ICL	Inhibition* (IC ₅₀)	Remarks
30	2011	Peptide inhibitor [43]	Synthetic	—	<i>Mycobacterium tuberculosis</i>	Inhibition rate 38.2–47.92%	Samples contain no peptide inhibitor or ICL in reaction system as controls
3-Nitropropionamides derivatives [40]							
31	2011		Synthetic	—	<i>Mycobacterium tuberculosis</i>	0.1 μM	Positive control IC ₅₀ of 3-nitropropionate = 116.0 μM (good inhibitory)
Pyruvate-isoniazid analog with their copper complex [45]							
32	2012		Synthetic	—	<i>Mycobacterium tuberculosis</i>	Inhibition rate 6–92%	Control docking using pyruvic acid
Bahamaolides A (macrolide) [56]							
33	2012		<i>Streptomyces</i> sp.	Actinomycete (Actinobacteria)	<i>Candida albicans</i>	10.8 μM	Positive control IC ₅₀ of 3-nitropropionate = 20.1 μM (high inhibitory)

TABLE 1: Continued.

Number	Published year	Inhibitor	Source	Description	Target ICL	Inhibition* (IC ₅₀)	Remarks
34	2012	Beta-carboline alkaloid [57]	<i>Synoicum</i> sp.	Ascidian (sea squirt)	<i>Candida albicans</i>	48.2–68.9 μ M	Positive control IC ₅₀ of 3-nitropropionate = 38.6 μ M (weak inhibitory)

35	2012	Sphingolipid [58]	<i>Spirastrella abata</i>	Marine sponge	<i>Candida albicans</i>	2–87 μ M	Positive control IC ₅₀ of 3-nitropropionate = 1.0 μ M (weak to moderate inhibitory)

TABLE I: Continued.

Number	Published year	Inhibitor	Source	Description	Target ICL	Inhibition* (IC ₅₀)	Remarks
Thio benzamide [66]							
36	2012		Synthetic	—	<i>Mycobacterium tuberculosis</i>	21–23% inhibition at 10 μmol/L	Positive control 3-nitropropionate has 25% inhibition at 10–100 μmol/L
Salicylanilide derivatives [67]							
38	2012		Synthetic	—	<i>Mycobacterium tuberculosis</i>	22–59% inhibition at 10–100 μmol/L	Positive control 3-nitropropionate has 25–67% inhibition at 10–100 μmol/L

TABLE I: Continued.

Number	Published year	Inhibitor	Source	Description	Target ICL	Inhibition* (IC ₅₀)	Remarks
		Tris-aromatic furanones [59]					
39	2013		<i>Synoicum</i> sp.	Ascidian (sea squirt)	<i>Candida albicans</i>	7.62–10.36 μ M	Positive control IC ₅₀ of 3-nitropropionate = 13.91 μ M (Good inhibitory)

TABLE I: Continued.

Number	Published year	Inhibitor	Source	Description	Target ICL	Inhibition * (IC ₅₀)	Remarks
40	2013	Heptapeptide [44]	Synthetic	—	<i>Mycobacterium tuberculosis</i>	126 μ M	Positive control IC ₅₀ of 3-nitropropionate = 50.7 μ M (good inhibitory)

*Inhibition default unit is IC₅₀ unless other units are mentioned in the table.
*Inhibitory potential of potential inhibitors was evaluated by the respective authors.

Besides, many synthetic compounds were assayed on *Candida albicans* ICL to test their inhibitory potential as well, for instance, hydroquinone derivatives [62], bromophenols [63], analog of indole-containing natural compounds [64], and brominated resorcinol dimer [65]. Their IC_{50} were 0.28–1.02 mM, 2.65 μ M, 75 μ M, and 28 μ M, respectively.

3. Conclusion and Future Prospect

The pace of research in ICL has increased ever since the solution of the MTB ICL crystal structure [5] in 2000. Since then, ICL fundamental research has showed its potential as a drug target for latent TB treatment. The outcome also showed evidence that ICL is a persistence factor for MTB [3, 5, 12] but remains safe to be targeted [9]. With sufficient level of confidence for ICL as a potential drug target, Glaxo-SmithKline (in collaboration with Global TB Alliance) has performed the first ever high-throughput screening (HTS) in 2000 but has terminated in 2005 after screening about 900,000 compounds as the outcome was modestly successful [34, 68]. The second HTS was reported in 2004, which was a HTS services by the Tuberculosis Antimicrobial Acquisition and Coordinating Facility (TAACF, an anti-TB program established by National Institute of Health (NIH)). This HTS screening through ChemBridge library which consist of 100,997 compounds has ended in 2009 with modest success too [69, 70]. The third HTS against 465 types of traditional Chinese herbs was carried out in 2006 [30]. Since the era of ICL potential inhibitor screening started, articles and reports were released every year till present. In this paper, we have summarized most of the potential inhibitors found or investigated throughout these years in tabulate form (Table 1).

To look for more potential ICL inhibitors, generally, the research method can be divided into biological assay and *in silico* approach. Biological assay usually refers either to whole cell assay or enzymatic assay that is implemented in high-throughput screening [30, 68, 69]. Apart from biological assay, *in silico* approach of virtual screening or ensemble docking (namely, molecular dynamic simulation-enhanced virtual screening) could be integrated into the current screening strategy to further reduce the failure cost in lead identification stage. Ensemble docking is a rather established *in silico* approach in the field of computer aided drug design, yet to be applied in ICL studies. Unlike conventional virtual screening, ensemble docking is able to address the degree of freedom during molecular docking process and hence increase the chances of better hit for potential inhibitor. As a complementary approach, rational drug design too is able to contribute in lead identification as well as lead optimization. The former could be either used to newly design potential inhibitor or used to combine the features of potential inhibitors obtained from the biological or virtual screening; the latter could enhance the binding affinity of a potential inhibitor, in order to achieve balance score between IC_{50} , drug likeliness, and drug delivery [35–45]. Combination of both rational drug design and modified HTS (ensemble docking) might be a better approach when compared with only either one method.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

The authors would like to acknowledge the contribution of the Malaysian Ministry of Education for providing funding for Fundamental Research Grant Scheme (FRGS; 203/CIPPM/6711439). Thanks also are due to the support from ADAPT Research Cluster, Centre for Research Initiatives, Clinical & Health Sciences of Universiti Sains Malaysia. Y.-V. Lee would like to acknowledge Malaysia Ministry of Science, Technology and Innovation for National Science Fellowship. Special thanks are due to Dr. G. J. Tye for proofreading this paper.

References

- [1] A. Bairoch, "The ENZYME database in 2000," *Nucleic Acids Research*, vol. 28, no. 1, pp. 304–305, 2000.
- [2] L. G. Wayne and K. Y. Lin, "Glyoxylate metabolism and adaptation of *Mycobacterium tuberculosis* to survival under anaerobic conditions," *Infection and Immunity*, vol. 37, no. 3, pp. 1042–1049, 1982.
- [3] E. J. Muñoz-Elías and J. D. McKinney, "*Mycobacterium tuberculosis* isocitrate lyases 1 and 2 are jointly required for in vivo growth and virulence," *Nature Medicine*, vol. 11, no. 6, pp. 638–644, 2005.
- [4] K. L. Britton, S. J. Langridge, P. J. Baker et al., "The crystal structure and active site location of isocitrate lyase from the fungus *Aspergillus nidulans*," *Structure*, vol. 8, no. 4, pp. 349–362, 2000.
- [5] V. Sharma, S. Sharma, K. H. Z. Bentrup et al., "Structure of isocitrate lyase, a persistence factor of *Mycobacterium tuberculosis*," *Nature Structural & Molecular Biology*, vol. 7, no. 8, pp. 663–668, 2000.
- [6] K. L. Britton, I. S. B. Abeysinghe, P. J. Baker et al., "The structure and domain organization of *Escherichia coli* isocitrate lyase," *Acta Crystallographica D*, vol. 57, no. 9, pp. 1209–1218, 2001.
- [7] R. C. DeMattei, R. S. Feigelson, and P. C. Weber, "Factors affecting the morphology of isocitrate lyase crystals," *Journal of Crystal Growth*, vol. 122, no. 1–4, pp. 152–160, 1992.
- [8] E. Giachetti, G. Pinzauti, R. Bonaccorsi, M. Teresa Vincenzini, and P. Vanni, "Isocitrate lyase from higher plants," *Phytochemistry*, vol. 26, no. 9, pp. 2439–2446, 1987.
- [9] M. F. Dunn, J. A. Ramírez-Trujillo, and I. Hernández-Lucas, "Major roles of isocitrate lyase and malate synthase in bacterial and fungal pathogenesis," *Microbiology*, vol. 155, no. 10, pp. 3166–3175, 2009.
- [10] J.-M. Li, N. Li, D.-Y. Zhu, L.-G. Wan, Y.-L. He, and C. Yang, "Isocitrate lyase from *Mycobacterium tuberculosis* promotes survival of *Mycobacterium smegmatis* within macrophage by suppressing cell apoptosis," *Chinese Medical Journal*, vol. 121, no. 12, pp. 1114–1119, 2008.
- [11] K. H. Z. Bentrup, A. Miczak, D. L. Swenson, and D. G. Russell, "Characterization of activity and expression of isocitrate lyase in *Mycobacterium avium* and *Mycobacterium tuberculosis*," *Journal of Bacteriology*, vol. 181, no. 23, pp. 7161–7167, 1999.
- [12] T. A. Gould, H. van de Langemheen, E. J. Muñoz-Elías, J. D. McKinney, and J. C. Sacchetti, "Dual role of isocitrate lyase

- 1 in the glyoxylate and methylcitrate cycles in *Mycobacterium tuberculosis*," *Molecular Microbiology*, vol. 61, no. 4, pp. 940–947, 2006.
- [13] V. K. Singh and I. Ghosh, "Kinetic modeling of tricarboxylic acid cycle and glyoxylate bypass in *Mycobacterium tuberculosis*, and its application to assessment of drug targets," *Theoretical Biology and Medical Modelling*, vol. 3, no. 1, article 27, 2006.
- [14] B. A. McFadden and S. Purohit, "Itaconate, an isocitrate lyase directed inhibitor in *Pseudomonas indigofera*," *Journal of Bacteriology*, vol. 131, no. 1, pp. 136–144, 1977.
- [15] J. V. Schloss and W. W. Cleland, "Inhibition of isocitrate lyase by 3-nitropropionate, a reaction-intermediate analogue," *Biochemistry*, vol. 21, no. 18, pp. 4420–4427, 1982.
- [16] Y. H. Ko and B. A. McFadden, "Alkylation of isocitrate lyase from *Escherichia coli* by 3-bromopyruvate," *Archives of Biochemistry and Biophysics*, vol. 278, no. 2, pp. 373–380, 1990.
- [17] M. Finkelstein, H. Gold, and C. A. Paterno, "Pharmacology of itaconic acid and its sodium, magnesium, and calcium salts," *Journal of the American Pharmaceutical Association: American Pharmaceutical Association*, vol. 36, no. 6, pp. 173–179, 1947.
- [18] A. N. Booth, J. Taylor, R. H. Wilson, and F. DeEds, "The inhibitory effects of itaconic acid *in vitro* and *in vivo*," *The Journal of Biological Chemistry*, vol. 195, no. 2, pp. 697–702, 1952.
- [19] J. G. Greene, S.-S. Sheu, R. A. Gross, and J. T. Greenamyre, "3-Nitropropionic acid exacerbates *N*-methyl-D-aspartate toxicity in striatal culture by multiple mechanisms," *Neuroscience*, vol. 84, no. 2, pp. 503–510, 1998.
- [20] Y. H. Ko, B. L. Smith, Y. Wang et al., "Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP," *Biochemical and Biophysical Research Communications*, vol. 324, no. 1, pp. 269–275, 2004.
- [21] M. C. Shoshan, "3-bromopyruvate: targets and outcomes," *Journal of Bioenergetics and Biomembranes*, vol. 44, no. 1, pp. 7–15, 2012.
- [22] "W.H.O Tuberculosis Fact Sheets," <http://www.who.int/mediacentre/factsheets/fs104/en/index.html>.
- [23] D. G. Russell, "Mycobacterium tuberculosis: here today, and here tomorrow," *Nature Reviews Molecular Cell Biology*, vol. 2, no. 8, pp. 569–586, 2001.
- [24] J. C. Betts, P. T. Lukey, L. C. Robb, R. A. McAdam, and K. Duncan, "Evaluation of a nutrient starvation model of *Mycobacterium tuberculosis* persistence by gene and protein expression profiling," *Molecular Microbiology*, vol. 43, no. 3, pp. 717–731, 2002.
- [25] H. J. Saz and E. P. Hillary, "The formation of glyoxylate and succinate from tricarboxylic acids by *Pseudomonas aeruginosa*," *The Biochemical Journal*, vol. 62, no. 4, pp. 563–569, 1956.
- [26] D.-S. Shin, S. Kim, H.-C. Yang, and K.-B. Oh, "Cloning and expression of isocitrate lyase, a key enzyme of the glyoxylate cycle, of *Candida albicans* for development of antifungal drugs," *Journal of Microbiology and Biotechnology*, vol. 15, no. 3, pp. 652–655, 2005.
- [27] H.-S. Lee, T.-H. Lee, H. L. Ji et al., "Inhibition of the pathogenicity of *Magnaporthe grisea* by bromophenols, isocitrate lyase inhibitors, from the red alga *Odonthalia corymbifera*," *Journal of Agricultural and Food Chemistry*, vol. 55, no. 17, pp. 6923–6928, 2007.
- [28] A. Idnurm and B. J. Howlett, "Isocitrate lyase is essential for pathogenicity of the fungus *Leptosphaeria maculans* to canola (*Brassica napus*)," *Eukaryotic Cell*, vol. 1, no. 5, pp. 719–724, 2002.
- [29] T. R. Patel and B. A. McFadden, "*Caenorhabditis elegans* and *Ascaris suum*: inhibition of isocitrate lyase by itaconate," *Experimental Parasitology*, vol. 44, no. 2, pp. 262–268, 1978.
- [30] B. Bai, J.-P. Xie, J.-F. Yan, H.-H. Wang, and C.-H. Hu, "A high throughput screening approach to identify isocitrate lyase inhibitors from traditional Chinese medicine sources," *Drug Development Research*, vol. 67, no. 10, pp. 818–823, 2006.
- [31] J. Lu, J. Yue, J. Wu et al., "*In vitro* and *in vivo* activities of a new lead compound I2906 against *Mycobacterium tuberculosis*," *Pharmacology*, vol. 85, no. 6, pp. 365–371, 2010.
- [32] J. Liang, F. Zeng, A. Guo et al., "Microarray analysis of the chelerythrine-induced transcriptome of *Mycobacterium tuberculosis*," *Current Microbiology*, vol. 62, no. 4, pp. 1200–1208, 2011.
- [33] M. Krátký and J. Vinšová, "Advances in mycobacterial isocitrate lyase targeting and inhibitors," *Current Medicinal Chemistry*, vol. 19, no. 36, pp. 6126–6137, 2012.
- [34] R. Sharma, O. Das, S. G. Damle, and A. K. Sharma, "Isocitrate lyase: a potential target for anti-tubercular drugs," *Recent Patents on Inflammation & Allergy Drug Discovery*, vol. 7, no. 2, pp. 114–123, 2013.
- [35] D. Sriram, P. Yogeeswari, P. Senthilkumar et al., "Novel phthalazinyl derivatives: synthesis, antimycobacterial activities, and inhibition of *Mycobacterium tuberculosis* isocitrate lyase enzyme," *Medicinal Chemistry*, vol. 5, no. 5, p. 422, 2009.
- [36] D. Sriram, P. Yogeeswari, P. Senthilkumar et al., "Synthesis and antimycobacterial evaluation of novel phthalazin-4-ylacetamides against log- and starved phase cultures," *Chemical Biology & Drug Design*, vol. 75, no. 4, pp. 381–391, 2010.
- [37] D. Sriram, P. Yogeeswari, D. R. K. Vyas, P. Senthilkumar, P. Bhat, and M. Srividya, "5-Nitro-2-furoic acid hydrazones: design, synthesis and *in vitro* antimycobacterial evaluation against log and starved phase cultures," *Bioorganic & Medicinal Chemistry Letters*, vol. 20, no. 15, pp. 4313–4316, 2010.
- [38] D. Sriram, P. Yogeeswari, P. Senthilkumar, G. Naidu, and P. Bhat, "5-Nitro-2,6-dioxohexahydro-4-pyrimidinecarboxamides: synthesis, *in vitro* antimycobacterial activity, cytotoxicity, and isocitrate lyase inhibition studies," *Journal of Enzyme Inhibition and Medicinal Chemistry*, vol. 25, no. 6, pp. 765–772, 2010.
- [39] D. Banerjee, P. Yogeeswari, P. Bhat, A. Thomas, M. Srividya, and D. Sriram, "Novel isatinyl thiosemicarbazones derivatives as potential molecule to combat HIV-TB co-infection," *European Journal of Medicinal Chemistry*, vol. 46, no. 1, pp. 106–121, 2011.
- [40] D. Sriram, P. Yogeeswari, S. Methuku et al., "Synthesis of various 3-nitropropionamides as *Mycobacterium tuberculosis* isocitrate lyase inhibitor," *Bioorganic & Medicinal Chemistry Letters*, vol. 21, no. 18, pp. 5149–5154, 2011.
- [41] J. Li, D. Zhu, Z. Yi et al., "DNAzymes targeting the *icl* gene inhibit *icl* expression and decrease *Mycobacterium tuberculosis* survival in macrophages," *Oligonucleotides*, vol. 15, no. 3, pp. 215–222, 2005.
- [42] L. Ji, Q. Long, D. Yang, and J. Xie, "Identification of mannich base as a novel inhibitor of *Mycobacterium Tuberculosis* isocitrate by high-throughput screening," *International Journal of Biological Sciences*, vol. 7, no. 3, pp. 376–382, 2011.
- [43] Y.-H. Yin, X. Niu, B. Sun, G.-S. Teng, Y.-H. Zhao, and C.-M. Wu, "Screening peptide inhibitors using phage peptide library with isocitrate lyase in *Mycobacterium tuberculosis* as target," *Chemical Research in Chinese Universities*, vol. 27, no. 4, pp. 635–640, 2011.
- [44] X. Liu, Y. Zang, B. Sun, and Y. Yin, "Optimization of phage heptapeptide library-screening process for developing inhibitors of

- the isocitrate lyase homologue from *Mycobacterium tuberculosis*,” *Medicinal Chemistry Research*, vol. 23, no. 5, pp. 2543–2553, 2014.
- [45] D. Shingnapurkar, P. Dandawate, C. E. Anson et al., “Synthesis and characterization of pyruvate-isoniazid analogs and their copper complexes as potential ICL inhibitors,” *Bioorganic and Medicinal Chemistry Letters*, vol. 22, no. 9, pp. 3172–3176, 2012.
- [46] D.-S. Shin, T.-H. Lee, H.-S. Lee, J. Shin, and K.-B. Oh, “Inhibition of infection of the rice blast fungus by halisulfate 1, an isocitrate lyase inhibitor,” *FEMS Microbiology Letters*, vol. 272, no. 1, pp. 43–47, 2007.
- [47] H.-S. Lee, T.-H. Lee, S. H. Yang, H. J. Shin, J. Shin, and K.-B. Oh, “Sesterterpene sulfates as isocitrate lyase inhibitors from tropical sponge *Hippospongia* sp,” *Bioorganic & Medicinal Chemistry Letters*, vol. 17, no. 9, pp. 2483–2486, 2007.
- [48] M. Jung, H. J. Kyoung, B. Kim et al., “Meroditerpenoids from the brown alga *Sargassum siliquastrum*,” *Journal of Natural Products*, vol. 71, no. 10, pp. 1714–1719, 2008.
- [49] Y. H. Chang, D. Shin, Z. Na et al., “Dihydroxystyrene metabolites from an association of the sponges *Poecillastra wondoensis* and *Jaspis* sp,” *Journal of Natural Products*, vol. 71, no. 5, pp. 779–783, 2008.
- [50] N. Wang, J. Song, K. H. Jang et al., “Sesterterpenoids from the sponge *Sarcotragus* sp,” *Journal of Natural Products*, vol. 71, no. 4, pp. 551–557, 2008.
- [51] D. Lee, J. Shin, K.-M. Yoon et al., “Inhibition of *Candida albicans* isocitrate lyase activity by sesterterpene sulfates from the tropical sponge *Dysidea* sp,” *Bioorganic & Medicinal Chemistry Letters*, vol. 18, no. 20, pp. 5377–5380, 2008.
- [52] H.-S. Lee, K.-M. Yoon, Y.-R. Han et al., “5-Hydroxyindole-type alkaloids, as *Candida albicans* isocitrate lyase inhibitors, from the tropical sponge *Hyrtios* sp,” *Bioorganic & Medicinal Chemistry Letters*, vol. 19, no. 4, pp. 1051–1053, 2009.
- [53] S.-C. Chung, K. H. Jang, J. Park, C.-H. Ahn, J. Shin, and K.-B. Oh, “Sargachromanols as inhibitors of Na⁺/K⁺ ATPase and isocitrate lyase,” *Bioorganic & Medicinal Chemistry Letters*, vol. 21, no. 7, pp. 1958–1961, 2011.
- [54] J.-E. Jeon, J. Bae, K. J. Lee, K.-B. Oh, and J. Shin, “Scalarane sesterterpenes from the sponge *Hyatella* sp,” *Journal of Natural Products*, vol. 74, no. 4, pp. 847–851, 2011.
- [55] J. Bae, J.-E. Jeon, Y.-J. Lee et al., “Sesterterpenes from the tropical sponge *Coscinoderma* sp,” *Journal of Natural Products*, vol. 74, no. 8, pp. 1805–1811, 2011.
- [56] D.-G. Kim, K. Moon, S.-H. Kim et al., “Bahamaolides A and B, antifungal polyene polyol macrolides from the marine actinomycete *Streptomyces* sp,” *Journal of Natural Products*, vol. 75, no. 5, pp. 959–967, 2012.
- [57] T. H. Won, J.-E. Jeon, S.-H. Lee, B. J. Rho, K.-B. Oh, and J. Shin, “Beta-carboline alkaloids derived from the ascidian *Synoicum* sp,” *Bioorganic and Medicinal Chemistry*, vol. 20, no. 13, pp. 4082–4087, 2012.
- [58] K. H. Jang, Y. Lee, C. J. Sim, K.-B. Oh, and J. Shin, “Bioactive lipids from the sponge *Spirastrella abata*,” *Bioorganic & Medicinal Chemistry Letters*, vol. 22, no. 2, pp. 1078–1081, 2012.
- [59] C.-H. Ahn, T. H. Won, H. Kim, J. Shin, and K.-B. Oh, “Inhibition of *Candida albicans* isocitrate lyase activity by cadiolides and synoilides from the ascidian *Synoicum* sp,” *Bioorganic & Medicinal Chemistry Letters*, vol. 23, no. 14, pp. 4099–4101, 2013.
- [60] R. Hautzel, H. Anke, and W. S. Sheldrick, “Mycenon, a new metabolite from a *Mycena* species TA 87202 (basidiomycetes) as an inhibitor of isocitrate lyase,” *The Journal of Antibiotics*, vol. 43, no. 10, pp. 1240–1244, 1990.
- [61] H. J. Kyoung, J.-E. Jeon, S. Ryu, H.-S. Lee, K.-B. Oh, and J. Shin, “Polyoxygenated diterpenes from the sponge *Phorbasp* sp,” *Journal of Natural Products*, vol. 71, no. 10, pp. 1701–1707, 2008.
- [62] H.-C. Yang, J. Yu, K.-B. Oh et al., “Synthesis and evaluation of hydroquinone derivatives as inhibitors of isocitrate lyase,” *Archives of Pharmacal Research*, vol. 30, no. 8, pp. 955–961, 2007.
- [63] K.-B. Oh, H. B. Jeon, Y.-R. Han et al., “Bromophenols as *Candida albicans* isocitrate lyase inhibitors,” *Bioorganic & Medicinal Chemistry Letters*, vol. 20, no. 22, pp. 6644–6648, 2010.
- [64] Y.-J. Lee, Y.-R. Han, W. Park, S.-H. Nam, K.-B. Oh, and H.-S. Lee, “Synthetic analogs of indole-containing natural products as inhibitors of sortase A and isocitrate lyase,” *Bioorganic & Medicinal Chemistry Letters*, vol. 20, no. 23, pp. 6882–6885, 2010.
- [65] E. Bouthenet, K.-B. Oh, S. Park, N. K. Nagi, H.-S. Lee, and S. E. Matthews, “Synthesis and antimicrobial activity of brominated resorcinol dimers,” *Bioorganic & Medicinal Chemistry Letters*, vol. 21, no. 23, pp. 7142–7145, 2011.
- [66] J. Kozic, E. Novotná, M. Volková et al., “Synthesis and *in vitro* antimycobacterial and isocitrate lyase inhibition properties of novel 2-methoxy-2'-hydroxybenzanilides, their thioxo analogues and benzoxazoles,” *European Journal of Medicinal Chemistry*, vol. 56, pp. 108–119, 2012.
- [67] M. Krátký, J. Vinová, E. Novotná et al., “Salicylanilide derivatives block *Mycobacterium tuberculosis* through inhibition of isocitrate lyase and methionine aminopeptidase,” *Tuberculosis*, vol. 92, no. 5, pp. 434–439, 2012.
- [68] “IFPMA Status Report on Pharmaceutical Industry R&D for Diseases of the Developing World,” http://www.ifpma.org/file-admin/content/Innovation/Research%20and%20Dev/Collaborative_Innovation_Models/Status_RnD_for_DDW_Nov2011.pdf.
- [69] S. Ananthan, E. R. Faaleolea, R. C. Goldman et al., “High-throughput screening for inhibitors of *Mycobacterium tuberculosis* H37Rv,” *Tuberculosis*, vol. 89, no. 5, pp. 334–353, 2009.
- [70] C. Sala and R. C. Hartkoorn, “Tuberculosis drugs: new candidates and how to find more,” *Future Microbiology*, vol. 6, no. 6, pp. 617–633, 2011.